Guanazole was given to 27 patients with advanced neoplastic diseases, mostly acute leukemia, by continuous i.v. infusion in 5-day courses. Toxicity was manifest mainly by myelosuppression, but drug fever, mucositis, rash, and alkalosis were also observed.
Complete remission was achieved in two out of 14 patients with previously treated acute myelocytic leukemia, and an M1 marrow occurred in one out of four patients with advanced acute lymphocytic leukemia. Most of the effects of guanazole appear to be dose related, with a narrow therapeutic index. This is the first evidence of therapeutic activity of guanazole in man.
This investigation was supported by USPHS Research Grants CA-2599, CA-5834, and CA-07918 from the National Cancer Institute.